Loading…

Eli Lilly announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Fogelsville, Lehigh Valley, Pennsylvania, focused on next-generation weight-loss therapies including retatrutide. The facility is expected to create 850 permanent jobs and begin operations in 2031.
“Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility.”stocktitan.net
Summarized from public sources; check the original articles before acting on it.